NCT01538134|Unknown
Loading search results
Sponsor study identifier
observational
90
1 country
1
Study Start
June 2015
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
February 2016
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 2016
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The Antiphospholipid Syndrome is an immune disease where the presence of antibodies directed against cell membrane phospholipids (antiphospholipid antibodies) can cause an hypercoagulable state that causes thrombosis and obstetric complications (miscarriages, stillbirths). Since 1999 the Sapporo Criteria for Antiphospholipid Syndrome diagnosis includes the development of fetal growth restriction (diagnosed postpartum), but this was done without solid evidence of a relation between the two or using the most common form of fetal growth restriction diagnosis (ultrasound). Our study will try to add information to this particular point.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2016
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 19, 2012
Actual (reported)February 23, 2012
Actual (reported)June 2015
Date type not reportedThis date has not been verified as actual or estimated.
February 2016
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
March 2016
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Lupus anticoagulant
Number of cases positive for Lupus Anticoagulant.
8 months
Anticardiolipin antibodies
Number of cases with high/medium levels of IgG/IgM of anticardiolipin antibodies.
10 months
B2 Glycoprotein I
Number of cases with levels of B2 Glycoprotein I \> 99%
10 months
Patients with ultrasonographic diagnosis of fetal growth restriction.
Patients with normal pregnancies at term.
Pregnant patients admitted for fetal growth restriction (cases) and normal patients in labor at term (controls).
Saint Thomas Maternity Hospital
Panama City, Provincia de Panamá, Panama
Osvaldo Reyes, MD
Saint Thomas Hospital, Panama
First Submitted
February 19, 2012
First Posted
February 23, 2012
Study Start
June 2015
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
February 2016
Monitoring Anticoagulant Therapy in Antiphospholipid Syndrome
Clinical Outcomes of Primary Versus Secondary Antiphospholipid Syndrome
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 2016
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
January 5, 2015
Record last verified: 2015-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: